Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Inclusion Criteria: * Patients with recurrent ovarian cancer. Ovarian cancer = fallopian tube cancer, ovarian cancer, primary peritoneal cancer. The following histology types are eligible: * High grade serous * Endometrioid, grade 3 * Any histology with BRCA1 and/or BRCA2 deleterious mutation (germline or somatic) * Histologic confirmation of the original primary tumor is required via the pathology report (upload of report required) * Confirmation of BRCA1 and BRCA2 germline status is required for all entered patients (upload of report\[s\] required) * Tumor/somatic genomic testing can be provided or entered as not done (upload of report\[s\] required) * Homologous recombination deficiency (HRD) testing can be provided or entered as not done (upload of report\[s\] required) * Genetic/genomic testing results and HRD testing results, initially entered as not done, should be uploaded if they become available anytime during conduct of the study * Participants must have progressed by imaging while receiving PARP inhibitor therapy (irrespective of whether PARP inhibitor therapy was given as maintenance therapy or as primary recurrence therapy); rising CA125 only is not considered as evidence of progression * Platinum-resistant disease, defined as progression within \< 6 months from completion of platinum-based therapy, and inclusive of platinum refractory disease. The date should be calculated from the last administered dose of platinum therapy * Unlimi…